EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti‐HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone‐Fused Enediyne

Xueqiong Feng, Zhongqing Wen, Xiangcheng Zhu, Xiaohui Yan, Yanwen Duan, Yong Huang iD

Advanced Science · 2024-05 · 11 (17)

DOI: 10.1002/advs.202307865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 14.02.2024. Verfasst von Xueqiong Feng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya International Academy of Translational Medicine, Central South University, Changsha, Hunan, 410013, China. Hauptthemen laut MEDLINE: Liposomes, Enediynes, Erb-b2 Receptor Tyrosine Kinases, Anthraquinones. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hunan Key Research and Development Program, science and technology innovation Program of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although natural products are essential sources of small‐molecule antitumor drugs, some can exert substantial toxicities, limiting their clinical utility. Anthraquinone‐fused enediyne natural products are remarkably potent antitumor drug candidates, and uncialamycin and tiancimycin (TNM) A are under development as antibody‐drug conjugates. Herein, a novel drug delivery system is introduced for TNM A using anti‐human epidermal growth factor receptor 2 (HER2) immunoliposomes (ILs). Trastuzumab‐coated TNM A‐loaded ILs (HER2‐TNM A‐ILs) is engineered with an average particle size of 182.8 ± 2.1 nm and a zeta potential of 1.75 ± 0.12 mV. Compared with liposomes lacking trastuzumab, HER2‐TNM A‐ILs exhibited selective toxicity against HER2‐positive KPL‐4 and SKBR3 cells. Coumarin‐6, a fluorescent TNM A surrogate, is encapsulated within anti‐HER2 ILs; the resultant ILs have enhanced cellular uptake in KPL‐4 and SKBR3 cells when compared with control liposomes. Furthermore, ILs loaded with more Cy5.5 accumulated in KPL‐4 mouse tumors. A single HER2‐TNM A‐IL dose (0.02 mg kg −1 ) suppressed the growth of HER2‐positive KPL‐4 mouse tumors without apparent toxicity. This study not only provides a straightforward method for the effective delivery of TNM A against HER2‐positive breast tumors but also underscores the potential of IL‐based drug delivery systems when employing highly potent cytotoxins as payloads.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesEnediynesErb-b2 Receptor Tyrosine KinasesAnthraquinonesDrug Delivery SystemsAntineoplastic AgentsAnimalsMiceHumansCell Line, TumorFemaleDisease Models, AnimalTrastuzumabBreast Neoplasms

Stichwörter der Autor:innen

anthraquinone‐fused enediynebreast cancerimmunoliposomestiancimycin Atrastuzumab

Substanzen

LiposomesEnediynesErb-b2 Receptor Tyrosine KinasesAnthraquinonesAntineoplastic AgentsTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Xiangya International Academy of Translational Medicine, Central South University, Changsha, Hunan, 410013, China.
  • Hunan Engineering Research Center of Combinatorial Biosynthesis and Natural Product Drug Discover, Changsha, Hunan, 410011, China.
  • State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
  • National Engineering Research Center of Combinatorial Biosynthesis for Drug Discovery, Changsha, Hunan, 410011, China.
  • Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, Anhui, 230093, China.

ORCID-Profile: Yong Huang

Förderung

  • National Natural Science Foundation of China
  • Hunan Key Research and Development Program
  • science and technology innovation Program of Hunan Province
  • Chinese Ministry of Education 111 Project

Zitieren

APA

Feng, X., Wen, Z., Zhu, X., Yan, X., Duan, Y., & Huang, Y. (2024). Anti‐HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone‐Fused Enediyne. Advanced Science, 11(17). https://doi.org/10.1002/advs.202307865

Vancouver

Feng X, Wen Z, Zhu X, Yan X, Duan Y, Huang Y. Anti‐HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone‐Fused Enediyne. Advanced Science. 2024;11(17). doi:10.1002/advs.202307865

BibTeX
@article{Feng2024,
  author = {Feng, Xueqiong and Wen, Zhongqing and Zhu, Xiangcheng and Yan, Xiaohui and Duan, Yanwen and Huang, Yong},
  title = {Anti‐HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone‐Fused Enediyne},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {17},
  doi = {10.1002/advs.202307865}
}
Kostenlos starten →